Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05526443 · tracked via the Priya Life Science Austria tracker

Sponsor

Medical University of Graz

Phase

Observational

Started

2023-01-13

Last updated

2026-09-01

Condition(s) studied

Pancreatic CancerAdvanced Pancreatic Carcinoma

Investigational drug(s) / intervention(s)

all approved chemotherapeutic agents from second line

all approved chemotherapeutic agents from second line: all approved chemotherapeutic agents from second line

Study summary

To systematically collect and analyse real-world data on treatment patterns, clinical outcomes and toxicities among patients with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systematic treatment in Austria

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * 18 years, female and male * ECOG (Eastern Cooperative Oncology Group) Scale 0-2 * Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC * Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible * Signed informed consent for prospective patients, for retrospective cases no informed consent is required Exclusion Criteria: * Patients with locally advanced operable PDAC who do not receive palliative chemotherapy * Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy

Primary outcome measure(s)

Proportion of patients with locally advanced inoperable and/or metastatic PDAC undergoing palliative second line therapy after progression on first line chemotherapy — 24 months

Trial sites (14)

Facility	City	Region	Status
Medical University Graz Department of Oncology	Graz	Styria	Recruiting
Ordensklinikum Linz	Linz	Upper Austria	Recruiting
Landesklinikum Amstetten	Amstetten	Austria	Recruiting
Landesklinikum Feldkirch	Feldkirch	Austria	Recruiting
Krankenhaus der Barmherzigen Brüder	Graz	Austria	Recruiting
Universitätsklinikum Innsbruck,	Innsbruck	Austria	Recruiting
Landesklinikum Klagenfurt	Klagenfurt	Austria	Recruiting
Kepler University Hospital	Linz	Austria	Recruiting
Salzburg State Hospital, PMU University Clinic	Salzburg	Austria	Recruiting
Universitätsklinikum St. Pölten	Sankt Pölten	Austria	Recruiting
Barmherzige Schwestern Krankenhaus Wien	Vienna	Austria	Recruiting
Pancreatic Cancer Unit des Comprehensive Cancer Center (CCC-PCU)	Vienna	Austria	Recruiting
St. Josef Krankenhaus Wien	Vienna	Austria	Recruiting
Krankenhaus St. Vinzenz Zams	Zams	Austria	Recruiting

More Medical University of Graz trials in Austria

Cerebral Monitoring Using Pulsatile Near Infrared Spectroscopy in Neonates Recruiting

Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension Enrolling by invitation

Non-contrast Enhanced Cardiac Magnetic Resonance Normal Values and Imaging Protocols Recruiting

Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care Starting soon

Partial vs Total Knee Replacement for Medial Knee Osteoarthritis: a Prospective Randomized Controlled Study Starting soon

Other trials for the same condition

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) Active, not recruiting

Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery Recruiting

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer Recruiting

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05526443 on ClinicalTrials.gov ↗ ← All trials in Austria